Anthem Biosciences Rated Buy with Strong Growth Outlook

Nomura, a big finance company, thinks Anthem Biosciences is a good company to invest in.

They say Anthem is doing well because it helps make medicines and does research.

Nomura believes Anthem will grow a lot in the next few years and set a price target of Rs 740 for December 2026.

They like that Anthem works with many different kinds of medicines and has good relationships with its clients.

However, they also say that Anthem depends a lot on just a few medicines, which could be a problem.

Speciality chemical makers are also doing well because they supply companies that make medicines.

These companies have clearer growth and make more money than other chemical companies.

Indian companies that make bulk drugs are also investing in research to make more kinds of medicines and work with global drugmakers.

This is because global companies want to move their work away from China.

Overall, these companies are growing and doing well.